Local Oncologist Published With New Research on Breast Cancer Treatment

Highlands Oncology Group Physician Published in "Breast Cancer Research and Treatment"

Fayetteville (I-Newswire) January 21, 2014 - Dr. J. Thaddeus Beck, of Highlands Oncology Group (HOG), has been published in Breast Cancer Research and Treatment for his research on specific treatments of breast cancer.

The research entitled "Everolimus Plus Exemestane as First-Line Therapy in HR+, HER2- Advanced Breast Cancer in BOLERO-2" recently reached electronic publication.

The trial researched a new treatment of breast cancer among patients with a specific type of breast cancer. Local administers of the trial reported that, on average, patients' progression-free survival (PFC) rate tripled while maintaining quality of life.

PFC is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse, according to the National Cancer Institute (NCI). In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works, according to the NCI.

As breast cancer is a prevalent disease in the U.S., and the world, more research is continually sought.

Aside from skin cancer, breast cancer is the most common cancer among American women, according to the American Cancer Society (ACS). About 12 percent of women will develop breast cancer during their lifetime, according to the ACS.

Breast Cancer Research and Treatment is a medical journal which creates a marketplace for breast cancer topic, according to the publisher. It provides a place for presenting pertinent investigations and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.

Trials collaborating the research were administered by physicians internationally. Dr. Beck co-wrote the research and acted as an administrator of the trial.

As the leading cancer treatment and research facility in Northwest Arkansas, HOG is dedicated to the advancement of cancer treatment to provide patients with the best possible care and results.

Read more on the study here: http://www.ncbi.nlm.nih.gov/pubmed/24362951


Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer every day.

For more information visit www.HighlandsOncologyGroup.com.

About The Artist Evolution

The Artist Evolution is a boutique marketing, design and campaign management firm. We are available    More..as a constant marketing resource. We have the tools and experience to make your marketing campaign a success.Less..

Contact Information

The Artist Evolution
Derek Champagne
1753 N College
Ste 203
Phone : 4792220399

Published On:

January 21, 2014

Print Release:

Print Release

Visit The Artist Evolution Website

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.